Joseph E Italiano1, Albert T A Mairuhu, Robert Flaumenhaft. 1. Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. jitaliano@rics.bwh.harvard.edu
Abstract
PURPOSE OF REVIEW: Platelet microparticles were identified more than 40 years ago and are the most abundant circulating microparticle subtype. Yet fundamental questions about their formation and role in human disease are just beginning to be understood at the cellular and molecular level. This review will address mechanisms of platelet microparticle generation and evaluate our current understanding of their clinical relevance. RECENT FINDINGS: New evidence indicates that the majority of CD41 microparticles circulating in healthy individuals derive directly from megakaryocytes. CD41 microparticles also form from activated platelets upon loss of cytoskeleton-membrane adhesion, which occurs in a multitude of disease states characterized by elevated platelet microparticle levels. More recent studies have demonstrated that platelet microparticles function as a transport and delivery system for bioactive molecules, participating in hemostasis and thrombosis, inflammation, malignancy infection transfer, angiogenesis, and immunity. The mechanism of platelet microparticle participation in specific disease entities such as rheumatoid arthritis has been elucidated. SUMMARY: Continued research into how platelet microparticles are generated and function as a transcellular delivery system will advance our basic understanding of microparticle physiology and may enable new strategies for treatment of select disease entities.
PURPOSE OF REVIEW: Platelet microparticles were identified more than 40 years ago and are the most abundant circulating microparticle subtype. Yet fundamental questions about their formation and role in human disease are just beginning to be understood at the cellular and molecular level. This review will address mechanisms of platelet microparticle generation and evaluate our current understanding of their clinical relevance. RECENT FINDINGS: New evidence indicates that the majority of CD41 microparticles circulating in healthy individuals derive directly from megakaryocytes. CD41 microparticles also form from activated platelets upon loss of cytoskeleton-membrane adhesion, which occurs in a multitude of disease states characterized by elevated platelet microparticle levels. More recent studies have demonstrated that platelet microparticles function as a transport and delivery system for bioactive molecules, participating in hemostasis and thrombosis, inflammation, malignancy infection transfer, angiogenesis, and immunity. The mechanism of platelet microparticle participation in specific disease entities such as rheumatoid arthritis has been elucidated. SUMMARY: Continued research into how platelet microparticles are generated and function as a transcellular delivery system will advance our basic understanding of microparticle physiology and may enable new strategies for treatment of select disease entities.
Authors: Daniel L Sprague; Bennett D Elzey; Scott A Crist; Thomas J Waldschmidt; Robert J Jensen; Timothy L Ratliff Journal: Blood Date: 2008-01-15 Impact factor: 22.113
Authors: Robert Flaumenhaft; James R Dilks; Jennifer Richardson; Eva Alden; Sunita R Patel-Hett; Elisabeth Battinelli; Giannoula L Klement; Martha Sola-Visner; Joseph E Italiano Journal: Blood Date: 2008-09-18 Impact factor: 22.113
Authors: Khalid Al-Nedawi; Brian Meehan; Johann Micallef; Vladimir Lhotak; Linda May; Abhijit Guha; Janusz Rak Journal: Nat Cell Biol Date: 2008-04-20 Impact factor: 28.824
Authors: Yanfeng Wang; Rustem I Litvinov; Xinsheng Chen; Tami L Bach; Lurong Lian; Brian G Petrich; Susan J Monkley; Yasunori Kanaho; David R Critchley; Takehiko Sasaki; Morris J Birnbaum; John W Weisel; John Hartwig; Charles S Abrams Journal: J Clin Invest Date: 2008-02 Impact factor: 14.808
Authors: Melissa Piper Hunter; Noura Ismail; Xiaoli Zhang; Baltazar D Aguda; Eun Joo Lee; Lianbo Yu; Tao Xiao; Jeffrey Schafer; Mei-Ling Ting Lee; Thomas D Schmittgen; S Patrick Nana-Sinkam; David Jarjoura; Clay B Marsh Journal: PLoS One Date: 2008-11-11 Impact factor: 3.240
Authors: Julie Sahler; Katie Grimshaw; Sherry L Spinelli; Majed A Refaai; Richard P Phipps; Neil Blumberg Journal: Drug Discov Today Dis Mech Date: 2011-07-20
Authors: Adriana Vieira-de-Abreu; Robert A Campbell; Andrew S Weyrich; Guy A Zimmerman Journal: Semin Immunopathol Date: 2011-08-06 Impact factor: 9.623
Authors: Trevor P Fidler; Elizabeth A Middleton; Jesse W Rowley; Luc H Boudreau; Robert A Campbell; Rhonda Souvenir; Trevor Funari; Nicolas Tessandier; Eric Boilard; Andrew S Weyrich; E Dale Abel Journal: Arterioscler Thromb Vasc Biol Date: 2017-06-29 Impact factor: 8.311
Authors: Adam Corken; Susan Russell; Judith Dent; Steven R Post; Jerry Ware Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-06 Impact factor: 8.311
Authors: Melissa M Lee; Mehrab Nasirikenari; Charles T Manhardt; David J Ashline; Andrew J Hanneman; Vernon N Reinhold; Joseph T Y Lau Journal: J Biol Chem Date: 2014-02-18 Impact factor: 5.157